| Phagosomes are competent organelles for antigen cross-presentation M Houde, S Bertholet, E Gagnon, S Brunet, G Goyette, A Laplante, ... Nature 425 (6956), 402-406, 2003 | 953 | 2003 |
| New horizons in adjuvants for vaccine development SG Reed, S Bertholet, RN Coler, M Friede Trends in immunology 30 (1), 23-32, 2009 | 898 | 2009 |
| CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major Y Belkaid, E Von Stebut, S Mendez, R Lira, E Caler, S Bertholet, MC Udey, ... The Journal of Immunology 168 (8), 3992-4000, 2002 | 405 | 2002 |
| Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant RN Coler, S Bertholet, M Moutaftsi, JA Guderian, HP Windish, SL Baldwin, ... PloS one 6 (1), e16333, 2011 | 398 | 2011 |
| A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis S Bertholet, GC Ireton, DJ Ordway, HP Windish, SO Pine, M Kahn, T Phan, ... Science translational medicine 2 (53), 53ra74-53ra74, 2010 | 348 | 2010 |
| Programmed cell death in the unicellular protozoan parasite Leishmania N Lee, S Bertholet, A Debrabant, J Muller, R Duncan, HL Nakhasi Cell Death & Differentiation 9 (1), 53-64, 2002 | 347 | 2002 |
| Unleashing the potential of NOD-and Toll-like agonists as vaccine adjuvants C Maisonneuve, S Bertholet, DJ Philpott, E De Gregorio Proceedings of the National Academy of Sciences 111 (34), 12294-12299, 2014 | 319 | 2014 |
| Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice A Hekele, S Bertholet, J Archer, DG Gibson, G Palladino, LA Brito, ... Emerging microbes & infections 2 (1), 1-7, 2013 | 248 | 2013 |
| The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect S Calabro, E Tritto, A Pezzotti, M Taccone, A Muzzi, S Bertholet, ... Vaccine 31 (33), 3363-3369, 2013 | 213 | 2013 |
| Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis S Bertholet, GC Ireton, M Kahn, J Guderian, R Mohamath, N Stride, ... The Journal of Immunology 181 (11), 7948-7957, 2008 | 206 | 2008 |
| Programmed cell death in trypanosomatids and other unicellular organisms A Debrabant, N Lee, S Bertholet, R Duncan, HL Nakhasi International journal for parasitology 33 (3), 257-267, 2003 | 203 | 2003 |
| Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus F Bagnoli, MR Fontana, E Soldaini, RPN Mishra, L Fiaschi, E Cartocci, ... Proceedings of the National Academy of Sciences 112 (12), 3680-3685, 2015 | 197 | 2015 |
| Inferring Reasons for the Failure of Staphylococcus aureus Vaccines in Clinical Trials F Bagnoli, S Bertholet, G Grandi Frontiers in cellular and infection microbiology 2, 16, 2012 | 194 | 2012 |
| A synthetic adjuvant to enhance and expand immune responses to influenza vaccines RN Coler, SL Baldwin, N Shaverdian, S Bertholet, SJ Reed, VS Raman, ... PloS one 5 (10), e13677, 2010 | 171 | 2010 |
| Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo S Bertholet, R Goldszmid, A Morrot, A Debrabant, F Afrin, ... The Journal of Immunology 177 (6), 3525-3533, 2006 | 165 | 2006 |
| Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin M Brazzoli, D Magini, A Bonci, S Buccato, C Giovani, R Kratzer, V Zurli, ... Journal of virology 90 (1), 332-344, 2016 | 151 | 2016 |
| The importance of adjuvant formulation in the development of a tuberculosis vaccine SL Baldwin, S Bertholet, VA Reese, LK Ching, SG Reed, RN Coler The Journal of Immunology 188 (5), 2189-2197, 2012 | 143 | 2012 |
| Novel platforms for the development of a universal influenza vaccine A Kumar, TS Meldgaard, S Bertholet Frontiers in immunology 9, 333832, 2018 | 129 | 2018 |
| Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge D Magini, C Giovani, S Mangiavacchi, S Maccari, R Cecchi, JB Ulmer, ... PloS one 11 (8), e0161193, 2016 | 129 | 2016 |
| Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion SL Baldwin, N Shaverdian, Y Goto, MS Duthie, VS Raman, T Evers, ... Vaccine 27 (43), 5956-5963, 2009 | 119 | 2009 |
